These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 14746397)

  • 21. Risk segmentation related to the offering of a consumer-directed health plan: a case study of Humana Inc.
    Tollen LA; Ross MN; Poor S
    Health Serv Res; 2004 Aug; 39(4 Pt 2):1167-88. PubMed ID: 15230919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of the introduction of a chronic care model-based program on utilization of healthcare resources: the results of the Puglia care program.
    Robusto F; Bisceglia L; Petrarolo V; Avolio F; Graps E; Attolini E; Nacchiero E; Lepore V
    BMC Health Serv Res; 2018 May; 18(1):377. PubMed ID: 29801489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
    Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
    Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary care physician compensation method in medical groups: does it influence the use and cost of health services for enrollees in managed care organizations?
    Conrad DA; Maynard C; Cheadle A; Ramsey S; Marcus-Smith M; Kirz H; Madden CA; Martin D; Perrin EB; Wickizer T; Zierler B; Ross A; Noren J; Liang SY
    JAMA; 1998 Mar; 279(11):853-8. PubMed ID: 9516000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).
    Friedman M; Menjoge SS; Anton SF; Kesten S
    Pharmacoeconomics; 2004; 22(11):741-9. PubMed ID: 15250751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of access, a primary care program for indigent patients: inpatient and emergency room utilization.
    Davidson RA; Giancola A; Gast A; Ho J; Waddell R
    J Community Health; 2003 Feb; 28(1):59-64. PubMed ID: 12570173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and economic burden of breakthrough seizures.
    Divino V; Petrilla AA; Bollu V; Velez F; Ettinger A; Makin C
    Epilepsy Behav; 2015 Oct; 51():40-7. PubMed ID: 26255884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Costs of physical and mental comorbidities among employees: a comparison of those with and without bipolar disorder.
    Rajagopalan K; Kleinman NL; Brook RA; Gardner HH; Brizee TJ; Smeeding JE
    Curr Med Res Opin; 2006 Mar; 22(3):443-52. PubMed ID: 16574028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective analysis of global costs for maintenance of patients with ESRD.
    Ploth DW; Shepp PH; Counts C; Hutchison F
    Am J Kidney Dis; 2003 Jul; 42(1):12-21. PubMed ID: 12830452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan.
    Harris BN; West DS; Johnson J; Hong SH; Stowe CD
    J Manag Care Pharm; 2004; 10(5):449-55. PubMed ID: 15369428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Costs of Specialist Referrals From Employer-Sponsored Integrated Health Care Clinics Are Lower Than Those From Community Providers.
    Wright JR; Madhusudhan DK; Lawrence DC; Watts SA; Lord DJ; Whaley C; Bravata DM
    J Gen Intern Med; 2022 Nov; 37(15):3861-3868. PubMed ID: 35882712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective trial of a clinical pharmacy intervention in a primary care practice in a capitated payment system.
    Altavela JL; Jones MK; Ritter M
    J Manag Care Pharm; 2008; 14(9):831-43. PubMed ID: 19006440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health services utilization and cost for at-risk drinkers: rural and urban comparisons.
    Nietert PJ; French MT; Kirchner J; Han X; Booth BM
    J Stud Alcohol; 2004 May; 65(3):353-62. PubMed ID: 15222592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-Continuum Tool Is Associated with Reduced Utilization and Cost for Frequent High-Need Users.
    Hardin L; Kilian A; Muller L; Callison K; Olgren M
    West J Emerg Med; 2017 Feb; 18(2):189-200. PubMed ID: 28210351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.